Physician profile
Ellen Esther Wermter
NPI 1215452024
$251,163.85
in general payments reported to CMS, 2019-2025
8 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35K · 2022: $62K · 2023: $56K · 2024: $58K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $27K · Honoraria: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,515 · Food and Beverage: $6,199 · Education: $13.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,876.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,755.00 |
| Travel and Lodging | $27,216.94 |
| Honoraria | $20,725.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,515.00 |
| Food and Beverage | $6,199.22 |
| Education | $13.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $127,242.91 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $60,429.92 | 2021-2025 | |
| Axsome Therapeutics, INC. | $59,952.49 | 2023-2025 | Sunosi, Symbravo |
| Avadel Cns Pharmaceuticals, LLC | $2,179.65 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $1,297.58 | 2023-2025 | Inspire |
| Novo Nordisk INC | $25.00 | 2024 | Wegovy |
| Lilly USA, LLC | $21.30 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $15.00 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Wermter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.